SCHEMBL6133377

SCHEMBL6133377

COc1ccc(CC(=O)c2cccc(F)c2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 4/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
HTT P42858 4/20 0.41
ALOX12 P18054 2/20 0.41
LMNA P02545 4/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TSHR P16473 2/20 0.41
PARP1 P09874 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KCNH2 Q12809 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133524 0.87 NNMT (0.41) NPC1RAB9AALDH1A1KDM4ECES2
SCHEMBL6134193 0.85 CTNNB1 (0.50) NPC1RAB9AKDM4EHTTLMNA
SCHEMBL6134053 0.85 CES2 (0.51) NPC1RAB9AALDH1A1CES2CES1
SCHEMBL6134112 0.84 NPC1 (0.45) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL6134262 0.83 NNMT (0.42) NPC1RAB9AALDH1A1CES2CES1
SCHEMBL6134151 0.83 NNMT (0.45) NPC1RAB9AALDH1A1KDM4ECES1
SCHEMBL6135277 0.82 CES2 (0.41) NPC1RAB9AALDH1A1CES2CES1
SCHEMBL6134224 0.80 HTT (0.52) NPC1RAB9AALDH1A1HTTLMNA
SCHEMBL6134073 0.78 PDE4D (0.45) ALDH1A1KDM4EHPGDTSHRSMN1; SMN2
SCHEMBL6133689 0.78 PDE4D (0.54) NPC1ALDH1A1KDM4EHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 NPC1 4182/4885RAB9A 1824/4885ALDH1A1 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.